Capital World Investors
KALV

Capital World Investors’s KalVista Pharmaceuticals KALV Stock Holding History

Capital World Investors’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,808,583
Closed -$56.5M – 668
2026
Q1 		$56.5M Hold
2,808,583
– – 0.01% 443
2025
Q4 		$45.4M Sell
2,808,583
-369,004
-12% -$4.89M 0.01% 425
2025
Q3 		$38.7M Hold
3,177,587
– – 0.01% 441
2025
Q2 		$35.9M Hold
3,177,587
– – 0.01% 443
2025
Q1 		$36.7M Sell
3,177,587
-196,477
-6% -$2.01M 0.01% 427
2024
Q4 		$28.6M Hold
3,374,064
– – ﹤0.01% 444
2024
Q3 		$39.1M Buy
3,374,064
+146,444
+5% +$1.84M 0.01% 416
2024
Q2 		$38M Buy
3,227,620
+1,763,014
+120% +$20.6M 0.01% 405
2024
Q1 		$17.4M Buy
+1,464,606
New +$19.5M ﹤0.01% 463

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Capital World Investors's KALV Position: Q2 2026 in Review

Capital World Investors sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 2,808,583 shares — an estimated $56.5M sold.

Capital World Investors first reported a position in KALV in Q1 2024 and held it in 9 quarters. The position peaked at $56.5M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Capital World Investors reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Capital World Investors sold 2,808,583 KalVista Pharmaceuticals shares in Q2 2026, an estimated $56.5M.
  • Capital World Investors first reported a position in KalVista Pharmaceuticals in Q1 2024 and held it in 9 quarters.
  • Capital World Investors's KalVista Pharmaceuticals position peaked at $56.5M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Capital World Investors's 13F filing for Q2 2026, filed 12 Aug 2026.